Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
Semaglutide
Max Weight Loss0%
Studies15
Participants30,847
StatusAvailable

Semaglutide

Glucagon-like peptide-1 (GLP-1) receptor agonist

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics natural incretin hormones to regulate blood glucose and promote weight loss. Available as FDA-approved Ozempic® for Type 2 diabetes, Wegovy® for chronic weight management, and Rybelsus® as the first oral GLP-1 medication. Clinical trials demonstrate exceptional efficacy with 14.9% average weight loss and 26% reduction in major cardiovascular events.

Clinical Safety Profile

Reported Side Effects

Nausea (most common, typically mild and transient)
Vomiting and gastrointestinal upset
Diarrhea and abdominal discomfort
Decreased appetite (therapeutic effect)
Injection site reactions (subcutaneous forms)
Constipation and gastric delay
Headache and fatigue
Potential pancreatitis (rare but serious)

Side Effect Management (Clinical Trial Data)

Nausea
Common
44.2%
Diarrhea
Common
30.1%
Vomiting
Common
24.8%
Constipation
Common
23.4%
Abdominal Pain
Common
20.3%
Decreased Appetite
Common
18.6%
Injection Site Reactions
Infrequent
6.8%

Side Effect Management Strategies

Nausea: Take with food, smaller meals, ginger supplements
Vomiting: Slower dose escalation, anti-emetics if severe
Diarrhea: Adequate hydration, probiotics, bland diet
Constipation: Increase fiber intake, adequate fluids, light exercise

Clinical Safety Metrics

Variable
Overall Safety Rating
Variable
Discontinuation Rate
Research
Approved Status

CONTRAINDICATIONS

• Medullary thyroid carcinoma (personal/family history)
• Multiple Endocrine Neoplasia Type 2 (MEN 2)
• Known hypersensitivity to semaglutide
• Severe gastroparesis or gastric outlet obstruction

Medical Disclaimer

Semaglutide is FDA-approved as Ozempic® for Type 2 diabetes, Wegovy® for chronic weight management, and Rybelsus® as oral GLP-1 therapy. This information is for educational purposes and should not replace consultation with healthcare providers. Individual results may vary. Prescribing information and medical supervision are required for all therapeutic uses.